Literature DB >> 19653721

Introduction of the 7th edition eyelid carcinoma classification system from the American Joint Committee on Cancer-International Union Against Cancer staging manual.

Darryl J Ainbinder1, Bita Esmaeli, Stephen C Groo, Paul T Finger, Joseph P Brooks.   

Abstract

CONTEXT: The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer commissioned the Ophthalmic Oncology Task Force to modify and update the ophthalmic chapters of the 7th edition of the AJCC Cancer Staging Manual.
OBJECTIVE: To review the existing eyelid carcinoma chapter in the 6th edition of the AJCC Cancer Staging Manual for its clinical and research utility and to seek evidence-based revisions with the strongest medical foundation to use in updating the anatomically based TNM cancer staging system manual. DATA SOURCES: The 4-year Ophthalmic Oncology Task Force consisted of 45 tumor specialists from 10 countries and an extensive internal and external peer review process. The 10-member Carcinoma of the Eyelid team included a diverse group of international authors. The group included extensive representation by clinicians, pathologists, surgeons, radiation therapists, and cancer registrars, all with advanced, ophthalmic cancer-related areas of subspecialty. Data sources included the above expertise applying a worldwide medical literature search, with no discrimination based on language, country of origin, discipline source, specialty source, or surgical practice.
CONCLUSIONS: Revisions were made to the TNM classification in areas with the strongest basis in evidence and practical effect. Lymph node staging data were expanded markedly to reflect its significant prognostic value. T3 and T4 were redefined and stage groupings were added that applied current understanding in tumor biology, respected site-specific risk factors, and provided greater correlation with the common language of the overall AJCC Cancer Staging Manual. Evidence-based biomarkers and data-field modifiers were included to capture additional pathologically and clinically substantiated prognostic factors.

Entities:  

Mesh:

Year:  2009        PMID: 19653721     DOI: 10.5858/133.8.1256

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  15 in total

1.  Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea.

Authors:  Youn Joo Choi; Hyun Chul Jin; Min Joung Lee; Namju Kim; Ho-Kyung Choung; Sang In Khwarg
Journal:  Jpn J Ophthalmol       Date:  2014-04-25       Impact factor: 2.447

2.  Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.

Authors:  Min Joung Lee; Namju Kim; Ho-Kyung Choung; Ji-Young Choe; Sang In Khwarg; Ji Eun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-04       Impact factor: 4.553

3.  Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Authors:  Tengteng Wang; Tao Zhang; Xiaoxue Han; X I Liu; Naikang Zhou; Yang Liu
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

4.  American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival.

Authors:  Bita Esmaeli; Qasiem J Nasser; Hilda Cruz; Melissa Fellman; Carla L Warneke; Doina Ivan
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

Review 5.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

6.  Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.

Authors:  Swathi Kaliki; Adit Gupta; Mohammed Hasnat Ali; Anuradha Ayyar; Milind N Naik
Journal:  Int Ophthalmol       Date:  2016-02-01       Impact factor: 2.031

7.  Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma.

Authors:  Ji-Jin Yao; Guan-Qun Zhou; Xiao-Li Yu; Ling-Long Tang; Lei Chen; Yan-Ping Mao; Li Lin; Lu-Lu Zhang; Jian-Yong Shao; Ying Guo; Jun Ma; Ying Sun
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

8.  Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer.

Authors:  Yuka Asano; Shinichiro Kashiwagi; Naoyoshi Onoda; Kento Kurata; Tamami Morisaki; Satoru Noda; Tsutomu Takashima; Masahiko Ohsawa; Seiichi Kitagawa; Kosei Hirakawa
Journal:  Br J Cancer       Date:  2016-01-12       Impact factor: 7.640

9.  Immunohistochemical expression of X-linked inhibitor of apoptosis in eyelid sebaceous gland carcinoma predicts a worse prognosis.

Authors:  Perumal Jayaraj; Seema Sen; P S Dhanaraj; Romika Jhajhria; Shalu Singh; Vijay Kumar Singh
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

10.  Long Non-Coding RNA TP53TG1 Upregulates SHCBP1 to Promote Retinoblastoma Progression by Sponging miR-33b.

Authors:  Hongyi Wang; Zhen Zhang; Yue Zhang; Shihai Liu; Li Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.